Anzeige
Mehr »
Sonntag, 20.09.2026 - Börsentäglich über 12.000 News
114 Proben. 114 mit Gallium.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6VA | ISIN: FR0004065605 | Ticker-Symbol: MEB
Stuttgart
18.09.26 | 21:46
21,600 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
CAC Mid 60
1-Jahres-Chart
MEDINCELL SA Chart 1 Jahr
5-Tage-Chart
MEDINCELL SA 5-Tage-Chart
RealtimeGeldBriefZeit
21,38021,94018:37
21,60021,90018.09.

Aktuelle News zur MEDINCELL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.09.Medincell to Participate in Upcoming Investor Conferences397Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation...
► Artikel lesen
08.09.Medincell: Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting475Regulatory News: Medincell (Paris:MEDCL): The Annual General Meeting and Extraordinary General Meeting will be held at Medincell's headquarters (3 rue des Frères Lumière, 34830 Jacou, France)...
► Artikel lesen
01.09.Medincell Taps Edna Venneker as Chief Medical Officer3
01.09.Medincell Appoints Edna Venneker, MD, as Chief Medical Officer405Experienced international pharmaceutical executive with a strong track record in clinical development, regulatory strategy, program execution and portfolio leadership Former Head of Development...
► Artikel lesen
11.08.Medincell's Dr Grace Kim to Participate in Piper Sandler CNS Symposium882Regulatory News: Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across...
► Artikel lesen
MEDINCELL Aktie jetzt für 0€ handeln
11.08.Medincell's Dr Grace Kim to Participate in Piper Sandler CNS Symposium772Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic...
► Artikel lesen
29.07.Medincell: UZEDY: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook468Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY U.S. net sales reached a record $77 million in Q2 2026, up 43%...
► Artikel lesen
28.07.Medincell Announces the Availability of Its 2025-26 Universal Registration Document Including the Annual Financial and CSR Reports564Regulatory News: Medincell (Paris:MEDCL): The 2025-26 Universal Registration Document (URD) filed with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference...
► Artikel lesen
28.07.Medincell proposes Elisabeth Svanberg for board of directors4
28.07.Medincell schlägt Elisabeth Svanberg für den Verwaltungsrat vor5
28.07.Medincell Continues to Strengthen and Renew Its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg446The Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at Medincell's upcoming Annual General Meeting Upon her election, 50% of Medincell's Board...
► Artikel lesen
15.07.Medincell Aligns Debt Maturity with Its Expected Revenue Growth Trajectory567More than 3 years extension of debt maturity to mid-2031, aligning it with expected revenue ramp-up primarily driven by marketed UZEDY and Olanzapine LAI, which is currently under regulatory review...
► Artikel lesen
06.07.Medincell: Half-Year Liquidity Contract Statement477Regulatory News: Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026:...
► Artikel lesen
16.06.MedinCell FY 2025-26 slides: royalty shift accelerates, olanzapine nears1
16.06.Medincell Reports FY 2025-26 Annual Results1.001A year marked by solid execution, with Continued UZEDY ramp-up, supporting royalty growth Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026...
► Artikel lesen
28.05.Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026611Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting...
► Artikel lesen
26.05.Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June624Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe...
► Artikel lesen
21.05.EMA nimmt Zulassungsantrag von Teva und Medincell für langwirksames Schizophrenie-Medikament an18
21.05.Medincell: The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults759The olanzapine long-acting injectable (TEV-'749 mdc-TJK) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks. If approved, TEV-'749...
► Artikel lesen
29.04.Medincell - UZEDY: Q1 2026 Net Sales Reached $63M, Up 62% Year-on-Year676Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY U.S. net sales reached $63 million in Q1 2026, representing a...
► Artikel lesen
Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1